CEOInterviews.AI
Start App
Get an email when Robert Langer gives a new interview
One email per new interview. Unsubscribe in one click.
Robert Langer
Institute Professor, MIT

Developing New Biomaterials & Nanosystems with Bob Langer

📅 Feb 21, 2025 Technology Licensing Office (TLO) 66 MIN 425 VIEWS 136 SEGMENTS · 2 SPEAKERS
In 2022, Dr. Langer presented on "Developing New Biomaterials & Nanosystems" as part of the Technology Licensing Office's Golden Speaker Series. Dr. Langer is one of nine Institute Professors at MIT – the highest honor that can be awarded to a faculty member. He has written more than 1,570 articles and has over 1,400 issued and pending patents worldwide. Dr. Langer’s patents have been licensed or sublicensed to over 400 pharmaceutical, chemical, biotechnology, and medical device companies. He is the most cited engineer in history and was named as one of the 25 most important individuals in bi...
Lauren 0:06 ↗
So for over 16 years I've had the absolute honor of working very closely with our next speaker, Bob Langer, and it is extremely humbling and my absolute pleasure to welcome Bob to the TLO's Golden Speaker Series this afternoon. Bob, for those who don't know him, is an Institute Professor here at MIT and a professor of both chemical engineering and biological engineering.
Highlighting Bob's vast accomplishments really would in fact be a presentation in and of itself, so I'm going to name a few, and I promised him I would not embarrass him. So here we go. Bob, in data, he's probably the most cited engineer in history and having authored more than 1,500 scientific articles. He's received over 40 honorary degrees from institutions worldwide.
He's received over 220 major awards including the Charles Stark Draper Prize, which is considered the equivalent of the Nobel Prize for engineers, the Millennium Prize which is the world's most preeminent award for breakthrough innovations, and the Priestley Medal which is the highest award of the American Chemical Society. Bob has been elected to the National Academy of Medicine, Engineering, and Sciences and is one of three living individuals who have actually received both the United States National Medal of Science and the National Medal of Technology and Innovation. So, we are in for a treat.
Bob here at MIT works at the interface of material science and biotechnology and has a couple of core focus areas including drug delivery based on lipids, polymers, and devices as well as regenerative medicine including tissue engineering and stem cell research. So, in the theme of this event being hosted by the Technology Licensing Office, Bob is recognized actually as one of history's most prolific inventors. He is—and the numbers actually really speak for themselves—I was looking at our database and was really thrilled to find that Bob's first disclosure to the TLO was actually in 1974. So, Bob has been contributing to inventions for almost a half a century and has contributed to 720 distinct inventions that have been disclosed to the MIT Licensing Office, and those disclosures have given rise to hundreds of patents.
And interesting, as I looked at the data, his inventions actually stunningly reflect collaborations both across institutions as well as across disciplines long before the concept of convergence was in vogue. His intellectual property has been licensed to dozens of companies including about 40 companies that are considered startups out of MIT. And these companies address a variety of problems, real world problems in fact. Some recent examples of companies include VitaKey which works in the field of nutrition, Lyndra Therapeutics which develops resident devices for drug delivery to the gastrointestinal tract, Sigilon Therapeutics which is developing cell-based replacement therapies for chronic disease, Frequency Therapeutics which is tackling hearing loss, Tissium which is using biomaterials for tissue reconstruction, and Suono Bio which is using ultrasound as a delivery platform. So those are just a few examples of how broad the technology reach is from the Langer Lab.
And without further ado, I'm happy to turn the stage over to Bob. We certainly look forward to hearing about his perspectives on his journey and how he approaches translation of technology and research to have impact in the real world. On a housekeeping note, we will have a questions and answer session at the end of the presentation, so think up some good questions, and for those of you joining virtually, please feel free to put your questions in the chat. Bob, over to you.

1 more exchange in this transcript

Sign in free to read the rest of this interview. No card required.

Sign in to read the full transcript

Cite this transcript

APA, MLA, BibTeX
APA

Langer, R. (2025, February 21). Developing New Biomaterials & Nanosystems with Bob Langer [Interview transcript]. Technology Licensing Office (TLO). CEOInterviews.AI. https://ceointerviews.ai/interview/3359251/

MLA

Robert Langer. "Developing New Biomaterials & Nanosystems with Bob Langer." Technology Licensing Office (TLO), 21 Feb. 2025. Transcript, CEOInterviews.AI, https://ceointerviews.ai/interview/3359251/.

BibTeX
@misc{langer2025_3359251,
  author       = {Robert Langer},
  title        = {Developing New Biomaterials \& Nanosystems with Bob Langer},
  howpublished = {Interview transcript, Technology Licensing Office (TLO). CEOInterviews.AI},
  year         = {2025},
  month        = {feb},
  url          = {https://ceointerviews.ai/interview/3359251/},
  note         = {Speaker-attributed transcript with timestamps}
}